Observational studyBMC cardiovascular disorders2026
Vericiguat in patients with acute coronary syndrome and reduced ejection fraction: the EVE-ACSrEF study.
Observational study in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06321094 (Vericiguat in Patients With Acute Coronary Syndrome and Reduced Ejection Fraction), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Vericiguat in Patients With Acute Coronary Syndrome and Reduced Ejection Fraction: The EVE-ACSrEF Study
Who cites it
1 citing paper in PubMed.
- Vericiguat in the Post-Stabilization Phase of HFrEF: Targeting Residual Risk Across the Ischemia-Decompensation Continuum.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundPreclinical research has demonstrated that vericiguat can improve myocardial microcirculation. However, real-world evidence of using vericiguat alongside guideline-directed medical therapy (GDMT) in patients with acute coronary syndrome (ACS) complicated by heart failure with reduced ejection fraction (HFrEF) remains limited.
methodsIn this prospective cohort study, 149 ACS patients with left ventricular ejection fraction (LVEF) below 45% were grouped by their treatment preference. Multivariable analyses were used to evaluate the effect of vericiguat on the composite endpoint of hospitalization for heart failure (HHF) or cardiovascular death (CVD). A linear mixed-effects model was used to analyze changes in LVEF and N-terminal pro-brain natriuretic peptide (NT-proBNP) from baseline to 12 months. Differences in the absolute values of Kansas City Cardiomyopathy Questionnaire quality of life (KCCQ-QoL) scores during the follow-up were also evaluated.
resultsIn this study, 75 patients (50.3%) received vericiguat plus GDMT treatment, while 74 patients (49.7%) received GDMT treatment alone. The average age of enrolled patients was 65 years, with approximately 17.4% being female. 33.6% were classified as NYHA class III heart failure, and the average LVEF was 38.11%. Over the 12-month follow-up, the composite endpoint event occurred in 5 (6.67%) of 75 patients in the vericiguat group and 13 (17.57%) of 74 patients in the GDMT group (hazard ratio [HR] 0.31 [95% confidence interval (CI) 0.10–0.96]; P = 0.041). By the end of the follow-up, LVEF improved significantly more with vericiguat (least squares mean [LSM] difference 3.31% [95%CI 0.58%-6.04%]; P = 0.018). From the first month, the vericiguat group demonstrated greater reductions in NT-proBNP (P = 0.004) and improvements in KCCQ-QoL (P = 0.042) than the GDMT group, which were maintained through follow-up. Adverse events were mild with vericiguat, similar to the GDMT group.
conclusionIn the first prospective cohort study focusing on patients with ACS and HFrEF, vericiguat plus GDMT treatment for 12 months reduced the risk of CVD and HHF, while improving cardiac function and quality of life.
trial registrationClinicalTrials.gov (NCT06321094). Registered on 06 March 2024, prior to the enrollment of the first participant. https://clinicaltrials.gov/search?cond=NCT06321094 .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.